Our 30-Year Journey Continues with an expansion of our sonodynamic therapy into blood cancers with a $46MM award from ARPA-H...

Tumor Regression and Improved Patient Performance are Among the Early Findings

Encouraging preliminary data from the ongoing DIPG clinical study to be presented at the 2023 Society for Neuro-Oncology Annual Meeting in Vancouver

Learn more about Cancer Commons, an organization providing emotional support, clinical trial recommendations and other services for people who have been diagnosed with advanced cancer.

Looking for support with DIPG? Read the Q&A with the Director of Nurse Navigation at My DIPG Navigator to learn more about this patient-centered organization.

https://www.youtube.com/watch?v=kq8HedjNQGA&t=16m40s

Highly accomplished Pediatric Oncologist from St. Jude Children’s Research Hospital and CMO for Novocure Brings Great Promise for People with Challenging Conditions

Company’s Phase 2 clinical trial aims to find meaningful clinical endpoints regarding tumor regression and survival rates.

Fast Company has listed SonALAsense as an honorable mention in the health category of their annual ‘World Changing Ideas Awards’.

Multisite study will test sonodynamic therapy in pediatric patients with diffuse intrinsic pontine glioma (DIPG).

April recently joined SonALAsense as Director of Patient Advocacy and Engagement, helping build alliances with patient and trade organizations / associations to raise awareness of, and educate on, sonodynamic therapy and recruit patients for recurrent glioblastoma (GBM) and diffuse intrinsic pontine glioma (DIPG) clinical trials.

Company has received Safe to Proceed letters from FDA for two clinical trials in life-threatening brain tumors, DIPG trial is open and actively recruiting, it has expanded its executive leadership team and scientific advisory board and completed a Series B funding round.